SOS1
Ras/Rac guanine nucleotide exchange factor 1
All Product Categories
-
SOS1 Related Products (82)
Related Products (82)
-
SOS1/EGFR-IN-1
0 ImagesSOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer. SOS1/EGFR-IN-1 inhibits effectively SOS1(IC50=42.13±1.55 nM) and EGFR(IC50=1.01±0.04 nM) by inhibiting their downstream effector molecules. SOS1/EGFR-IN-1 induces apoptosis and G1 phase cell cycle arrest, reducing angiogenesis and migration. SOS1/EGFR-IN-1 shows significant antitumor effects in prostate cancer cells PC-3 (IC50=0.45±0.03 μM).
-
(4S)-PROTAC SOS1 degrader-1 diTFA
0 ImagesCat. No.: HY-144657APurity: 98.09%
-
(S)-BAY-293
0 ImagesCat. No.: HY-114398ACAS No.: 2244904-69-4(S)-BAY-293 is a negative control of BAY 293. BAY 293 is a potent KRAS-SOS1 interaction inhibitor.
-
SOS1-IN-8
0 ImagesCat. No.: HY-144212CAS No.: 2759387-92-1SOS1-IN-8 is a potent SOS1 inhibitor with IC50s of 11.6 and 40.7 nM for SOS1-G12D and SOS1-G12V, respectively (WO2022017339A1, compound 2).
-
SOS1-IN-16
0 ImagesCat. No.: HY-153989CAS No.: 2930763-85-0
-
SOS1-IN-7
0 ImagesCat. No.: HY-144211CAS No.: 2755415-30-4SOS1-IN-7 (compound 18-p1) is a potent SOS1 inhibitor with IC50s of 20 and 67 nM for SOS1-G12D and SOS1-G12V, respectively.
-
SOS1-IN-25
0 ImagesCat. No.: HY-179443CAS No.: 3092446-09-5SOS1-IN-25 is an SOS1 inhibitor. SOS1-IN-25 exhibits inhibitory activity against KRASG12C/SOS1 complex formation (IC50 = 11.11 nM). SOS1-IN-25 leads to a dose-dependent decrease in pERK levels. SOS1-IN-25 can be used for the study of leukemia.
-
SOS1-IN-19
0 ImagesCat. No.: HY-176170SOS1-IN-19 (Compound 10i) is a potent inhibitor of SOS1 (Son of Sevenless 1) with an IC50 value of 165.2 nM. SOS1-IN-19 blocks KRAS activation by preventing GDP/GTP exchange in KRAS signaling pathway. SOS1-IN-19 is promising for research of KRAS-driven cancers (e.g., NSCLC and colorectal cancer).
-
PROTAC SOS1 degrader-5
0 ImagesCat. No.: HY-161173CAS No.: 2836273-61-9PROTAC SOS1 degrader-5 is a potent SOS1 PROTAC degrader with a DC50 value of 13 nM. PROTAC SOS1 degrader-5 induces CRBN-dependent ubiquitination and degradation of SOS1 protein, inhibits the proliferation of KRASG12C-mutated cancer cells, and suppresses tumor growth in xenograft models. PROTAC SOS1 degrader-5 can be used in studies related to KRASG12C-mutated non-small cell lung cancer.
-
SOS1 Ligand intermediate-4
0 ImagesCat. No.: HY-161635CAS No.: 3036155-94-6
-
RAS activator compound 1
0 ImagesRAS activator compound 1 (Compound 7c) is a RAS activator targeting the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 (SOS1). RAS activator compound 1 can activate the nucleotide exchange process and increase levels of active RAS-GTP in HeLa cells. RAS activator compound 1 can be used for research of RAS-driven tumor.
-
SOS1-IN-3
0 ImagesCat. No.: HY-145046CAS No.: 2359689-76-0SOS1-IN-3 is a potent SOS1 (son of sevenless homolog 1) inhibitor with an IC50 of 5 nM. SOS1-IN-3 has anticancer effects (WO2019122129A1; compound I-1).
-
SOS1 activator 2
0 ImagesCat. No.: HY-167768CAS No.: 2245237-54-9SOS1 activator 2 (Compound 65) is a benzimidazole derivative and a SOS1 activator. SOS1 activator 2 has a high binding affinity for SOS1 with a Kd of 9 nM. SOS1 activator 2 can regulate the Ras-ERK signaling pathway, which can be used in the study of cancer.
-
SOS1-IN-12
0 ImagesCat. No.: HY-144965CAS No.: 2654741-56-5SOS1-IN-12 is a potent son of sevenless homolog 1 (SOS1) inhibitor with a Ki of 0.11 nM for SOS1 and an IC50 of 47 nM for pERK. SOS1-IN-13 can be used for researching anticancer.
-
SOS1-IN-17
0 ImagesCat. No.: HY-168716SOS1-IN-17 (Compound 8d) is an orally active inhibitor for SOS1-KRASG12C interaction with an IC50 of 5.1 nM. SOS1-IN-17 inhibits ERK phosphorylation in DLD-1 cell with an IC50 of 18 nM. SOS1-IN-17 exhibits anti-proliferative activity in KRASG12C mutated Mia-Paca-2 cell with an IC50 of 0.11 μM. SOS1-IN-17 exhibits antitumor efficacy against pancreatic cancer in mouse model.
-
SOS1-IN-10
0 ImagesCat. No.: HY-144213CAS No.: 2758690-15-0SOS1-IN-10 is a potent SOS1 inhibitor with an IC50 of 13 nM for KRAS G12C-SOS1 (WO2022017519A1, compound 8).
-
PROTAC SOS1 degrader-6
0 ImagesCat. No.: HY-162281CAS No.: 3032282-51-9PROTAC SOS1 degrader-6 is a selective SOS1 PROTAC degrader with a DC50 of 43-130 nM. PROTAC SOS1 degrader-6 induces ubiquitination and degradation of SOS1 via the ubiquitin-proteasome system by recruiting the E3 ligase VHL. PROTAC SOS1 degrader-6 reduces the levels of phosphorylated MEK and ERK. PROTAC SOS1 degrader-6 exerts antiproliferative effects in KRAS-driven cancer cells. PROTAC SOS1 degrader-6 can be used in research related to KRASG12C-mutant cancers and chronic myeloid leukemia.
-
HH0043
0 ImagesCat. No.: HY-161714CAS No.: 2922069-42-7HH0043 (Compound 10f) is an orally active and potent SOS1 inhibitor, with IC50 value of 5.8 nM. HH0043 can be used for the research of cancer.
